Replies to post #732617 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Does not make much sense to wait for approval on GBM indication when the big pharma will be licensing combo trial for other cancer indications.

Ofcourse how dumb of me it does not matter if a new cancer drug is approved or not. Why would biotech develop a drug and bother to have an BLA or MAA submitted to an RA anyway? I mean Investor082 clearly knows it better so why on earth would a biotech have its drug approved?

Thank you Investor082 for the depth of your wisdom will lead us into a brighter future where left is right up is down north is south.

The insanity of shorts here is just beyond comprehension

[manibiotech]

Exactly 
LP has loaned money in the past at hefty interest rate  . If they were sure of upfront payment in Dec or Jan then why not loan your own money or borrow at high interest rate for 3-6 months rather than dilute at pennies

[SkyLimit2022]

zero82,

Thanks for posting your psychic predictions and sage investment advice, but I ran your post through the AI BS Detector and it was identified as bs.




The statement by “Investor082” is speculative and unsupported by evidence, relying instead on conjecture and prior assumptions. It dismisses critical facts about Northwest Biotherapeutics’ (NWBO) ongoing work, particularly the clinical trials and funding mechanisms that underpin their research.

1. Clinical Investigation and Funding Support
NWBO’s technology is currently under clinical investigation in trials that are receiving funding from peer-reviewed, highly competitive grants, including a Department of Defense (DoD) grant at Roswell Park Comprehensive Cancer Center and a National Institutes of Health (NIH) grant at UCLA. These grants represent significant validation of NWBO’s research from esteemed and independent scientific and governmental bodies. The assertion that NWBO lacks funding support is factually incorrect and ignores these concrete sources of financial and institutional backing.

2. Misrepresentation of Historical Context
The reference to a “similar trick NWBO deployed in 2017” concerning a colorectal cancer combination trial is both misleading and irrelevant to the current situation. That trial’s outcomes cannot be generalized to ongoing efforts, particularly given the distinct funding structures and scientific advancements since that time. Without specific, documented evidence connecting the two scenarios, this comparison is speculative at best and does not constitute reasoned analysis.

3. Unsupported Speculation About Financing Decisions
The claim that NWBO’s management decisions regarding share pricing reflect a lack of confidence in future funding or share price growth is unsubstantiated. Financial strategies, such as setting share prices or accepting loans, are multifactorial decisions influenced by market conditions, regulatory environments, and broader strategic goals. Speculating on the motivations behind these decisions without insider knowledge or evidence amounts to rumor rather than analysis.

4. Spreading Unfounded Misinformation
The overall tone and content of the statement reflect a pattern of disseminating unverified and misleading claims. It offers no concrete evidence to support the assertion that “no significant upfront payment” will be made or that NWBO is “dangling carrots” to influence shareholder behavior. Such rhetoric detracts from reasoned discourse and risks misinforming stakeholders.

In conclusion, the author of the statement is engaging in baseless speculation rather than evidence-based critique. NWBO’s ongoing clinical investigations, supported by peer-reviewed grants, underscore the legitimacy and promise of their technology, contradicting claims of a lack of funding or credible progress. Assertions to the contrary lack substantiation and should be recognized as misinformation rather than informed commentary.

Short and Distort Advisory

Investors are cautioned to critically assess online claims regarding biotechnology companies, as these can include disinformation intended to manipulate stock prices. Anonymous commentary on message boards often lacks context, credibility, or accountability and may seek to influence sentiment for personal gain.

For accurate and reliable information, consult licensed financial professionals, trusted oncologists, and peer-reviewed scientific literature. Avoid rumors and incomplete narratives, and rely on credible, full-context sources when evaluating investment opportunities or assessing a company’s potential.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175399357